Genitourinary Cancers

CT-P71 is being assessed in patients with locally advanced or metastatic urothelial carcinoma.

Alexander Z. Wei, MD, highlighted key clinical trials presented at ASCO GU and initiated at Columbia University to “move the needle” in bladder cancer.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Phase 2 Cyto-KIK findings showed that a subset of patients with high-risk kidney cancer exhibited responses and underwent monitoring post-cabozantinib.

Key abstracts across genitourinary cancers were presented across multiple oral sessions examining investigational treatments in select patient groups.

Zelenectide pevedotin demonstrated manageable safety among patients with advanced solid tumors in the phase 1/2 Duravelo-1 trial.

According to investigators, the lack of anti-tumor activity and immunogenicity results do not support the agent’s further development in metastatic CRPC.

Data from the QUILT-3.032 trial supported the Saudi approval of nogapendekin alfa plus BCG in adults with BCG-unresponsive NMIBC with carcinoma in situ.

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.

The phase 1 ARTISAN trial investigators plan to expand enrollment to patients with metastatic CRPC outside the US in the second half of 2026.

Stereotactic body radiotherapy alone may be feasible instead of immediate systemic therapy in select patients with oligometastatic cancer.

More than 80% of patients in cohort B of the QUILT-3.032 study avoided cystectomy at 36 months after treatment with nogapendekin alfa plus BCG.

Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.

The PSA response rate and radiographic PFS were similar with the 177Lu-based combination regimen vs the radiotracer alone in metastatic CRPC.

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.